Видео ютуба по тегу Poor-Risk Cytogenetics

Treating patients with poor-risk cytogenetics with venetoclax and HMAs
Treating patients with poor-risk cytogenetics with venetoclax and HMAs
Varied outcomes in patients with AML harboring poor-risk cytogenetics with or without TP53 mutation
Varied outcomes in patients with AML harboring poor-risk cytogenetics with or without TP53 mutation
AML Risk Stratification: Cytogenetics and Mutational Analysis - Part 1
AML Risk Stratification: Cytogenetics and Mutational Analysis - Part 1
Cytogenetics and High Risk Mutations in Multiple Myeloma – Dr. Shaina Rozell
Cytogenetics and High Risk Mutations in Multiple Myeloma – Dr. Shaina Rozell
Linking poor cytogenetics and outcomes in MDS
Linking poor cytogenetics and outcomes in MDS
The impact of cytogenetic-risk stratification on AML outcomes
The impact of cytogenetic-risk stratification on AML outcomes
Can KRd + HSCT overcome the poor prognosis of harboring a high-risk cytogenetic aberration?
Can KRd + HSCT overcome the poor prognosis of harboring a high-risk cytogenetic aberration?
AML: the cytogenetic risk score
AML: the cytogenetic risk score
Impact of cytogenetic abnormalities on OS following SCT in pediatric AML
Impact of cytogenetic abnormalities on OS following SCT in pediatric AML
Case 2: Double Refractory Patient with High-risk Cytogenetics
Case 2: Double Refractory Patient with High-risk Cytogenetics
R/R High Risk CLL: Personalized Management Based on Patient Characteristics and Cytogenetics
R/R High Risk CLL: Personalized Management Based on Patient Characteristics and Cytogenetics
Prof. Joseph Brandwein | Cytogenetic abnormalities in AML
Prof. Joseph Brandwein | Cytogenetic abnormalities in AML
The impact of cytogenetics and molecular genetics on outcomes in AML
The impact of cytogenetics and molecular genetics on outcomes in AML
Clinical Implications of Genetic Mutations in Myelodysplastic Syndromes
Clinical Implications of Genetic Mutations in Myelodysplastic Syndromes
Keith Pratz, MD, tells us about the epidemiology and cytogenetic risk associated with AML
Keith Pratz, MD, tells us about the epidemiology and cytogenetic risk associated with AML
Why should chromosome 1 abnormalities be assessed in all patients with MM?
Why should chromosome 1 abnormalities be assessed in all patients with MM?
T-ALL diagnosis: cytogenetics, genomics and risk assessment
T-ALL diagnosis: cytogenetics, genomics and risk assessment
Cytogenetics and Molecular Testing in MDS
Cytogenetics and Molecular Testing in MDS
Ixazomib, Pomalidomide and Dexamethasone (IxPd) in RRMM characterized with high-risk cytogenetics
Ixazomib, Pomalidomide and Dexamethasone (IxPd) in RRMM characterized with high-risk cytogenetics
Why is it important for #myeloma patients to know the cytogenetic abnormalities of their cancer?
Why is it important for #myeloma patients to know the cytogenetic abnormalities of their cancer?